OncoMatch/Clinical Trials/NCT06899126
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
Is NCT06899126 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Trastuzumab Deruxtecan and pembrolizumab for non-small cell lung cancer.
Treatment: Trastuzumab Deruxtecan · pembrolizumab · Pemetrexed · Chemotherapy — This clinical trial is designed to assess the efficacy and safety of trastuzumab deruxtecan (T-DXd; Enhertu®) in combination with pembrolizumab versus platinum-based chemotherapy in combination with pembrolizumab in participants with no prior therapy for locally advanced unresectable or metastatic non-squamous NSCLC, whose tumors have HER2-overexpressing and PD-L1 TPS \<50% without known AGA that have locally available therapies targeting their AGAs in first-line advanced/metastatic setting.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: HER2 (ERBB2) overexpression
assessment of HER2 and PD-L1 expression by central or Sponsor-specified laboratory
Required: HER2 (ERBB2) mutation
Has no known HER2 mutation based on existing test results (if approved or validated local test is available)
Required: PD-L1 (CD274) expression
assessment of HER2 and PD-L1 expression by central or Sponsor-specified laboratory
Disease stage
Required: Stage IV, IIIB, IIIC
Prior therapy
Cannot have received: systemic anticancer therapy
Exception: adjuvant or neoadjuvant therapy (including ICI or platinum-based regimen) allowed if last dose ≥6 months before first trial dose and no progression on or within 6 months of last dose
Has not been treated with systemic anticancer therapy for advanced or metastatic non-squamous NSCLC. Participants who received adjuvant or neoadjuvant therapy other than those listed below, including ICI (ie, anti-PD-1/PD-L1) or a platinum-based regimen, are eligible if the last dose of adjuvant/neoadjuvant therapy was given at least 6 months before the date of the first trial dose and should not have progressed on or within 6 months of the last dose date of adjuvant/neoadjuvant therapy.
Cannot have received: topoisomerase I inhibitor (including ADCs containing a chemotherapeutic agent targeting topoisomerase I)
Any agent, including an ADC, containing a chemotherapeutic agent targeting topoisomerase I.
Cannot have received: HER2-targeted antibody-based anticancer therapy
HER2-targeted antibody-based anticancer therapy.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Alaska Oncology & Hematology, LLC · Anchorage, Alaska
- Orange Coast Memorial Medical Center Fountain Valley · Fountain Valley, California
- California Research Institute · Los Angeles, California
- Los Angeles Cancer Network (LACN) · Los Angeles, California
- Providence Medical Foundation · Santa Rosa, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify